# Harmonic Inc.: financial statements, quarterly

HLIT · Nasdaq · CIK 851310 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hlit.md) · [Financials](/companies/hlit/financials.md) · [Filings](/companies/hlit/filings.md) · [Insiders](/companies/hlit/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hlit/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-29) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [127](/filings/0000851310-24-000094.md) | [(52.3) d](/filings/0001193125-26-067506.md) | [122](/filings/0000851310-25-000041.md) | [139](/filings/0000851310-25-000076.md) | [196](/filings/0001193125-25-264696.md) | [31.6 d](/filings/0001193125-26-067506.md) | [84.9](/filings/0001193125-26-221899.md) | [86.9](/filings/0001193125-26-353891.md) | [142](/filings/0001193125-25-264696.md) | [(53.0) d](/filings/0001193125-26-067506.md) | [122](/filings/0001193125-26-221899.md) | [133](/filings/0001193125-26-353891.md) |
| Cost of revenue | $m | [65.5](/filings/0000851310-24-000094.md) | [0.2 d](/filings/0001193125-26-067506.md) | [59.0](/filings/0000851310-25-000041.md) | [65.3](/filings/0000851310-25-000076.md) | [91.0](/filings/0001193125-25-264696.md) | [32.8 d](/filings/0001193125-26-067506.md) | [38.4](/filings/0001193125-26-221899.md) | [47.1](/filings/0001193125-26-353891.md) | [65.3](/filings/0001193125-25-264696.md) | [1.7 d](/filings/0001193125-26-067506.md) | [58.1](/filings/0001193125-26-221899.md) | [63.6](/filings/0001193125-26-353891.md) |
| Gross profit | $m | [61.7](/filings/0000851310-24-000094.md) | [(52.6) d](/filings/0001193125-26-067506.md) | [63.1](/filings/0000851310-25-000041.md) | [73.5](/filings/0000851310-25-000076.md) | [105](/filings/0001193125-25-264696.md) | [(1.2) d](/filings/0001193125-26-067506.md) | [46.5](/filings/0001193125-26-221899.md) | [39.8](/filings/0001193125-26-353891.md) | [77.1](/filings/0001193125-25-264696.md) | [(54.8) d](/filings/0001193125-26-067506.md) | [63.6](/filings/0001193125-26-221899.md) | [69.9](/filings/0001193125-26-353891.md) |
| Research and development | $m | [30.3](/filings/0000851310-24-000094.md) | [(26.3) d](/filings/0001193125-26-067506.md) | [30.7](/filings/0000851310-25-000041.md) | [28.8](/filings/0000851310-25-000076.md) | [30.1](/filings/0001193125-25-264696.md) | [(17.0) d](/filings/0001193125-26-067506.md) | [19.7](/filings/0001193125-26-221899.md) | [18.0](/filings/0001193125-26-353891.md) | [29.7](/filings/0001193125-25-264696.md) | [(14.2) d](/filings/0001193125-26-067506.md) | [20.9](/filings/0001193125-26-221899.md) | [21.2](/filings/0001193125-26-353891.md) |
| Selling, general and administrative | $m | [39.2](/filings/0000851310-24-000094.md) | [(43.0) d](/filings/0001193125-26-067506.md) | [38.9](/filings/0000851310-25-000041.md) | [39.8](/filings/0000851310-25-000076.md) | [35.9](/filings/0001193125-25-264696.md) | [(35.4) d](/filings/0001193125-26-067506.md) | [19.8](/filings/0001193125-26-221899.md) | [20.5](/filings/0001193125-26-353891.md) | [36.5](/filings/0001193125-25-264696.md) | [(30.4) d](/filings/0001193125-26-067506.md) | [22.3](/filings/0001193125-26-221899.md) | [24.6](/filings/0001193125-26-353891.md) |
| Operating income | $m | [(8.6)](/filings/0000851310-24-000094.md) | [17.5 d](/filings/0001193125-26-067506.md) | [(9.5)](/filings/0000851310-25-000041.md) | [(15.6)](/filings/0000851310-25-000076.md) | [35.4](/filings/0001193125-25-264696.md) | [64.5 d](/filings/0001193125-26-067506.md) | [7.0](/filings/0001193125-26-221899.md) | [(0.8)](/filings/0001193125-26-353891.md) | [9.8](/filings/0001193125-25-264696.md) | [(9.7) d](/filings/0001193125-26-067506.md) | [20.4](/filings/0001193125-26-221899.md) | [23.6](/filings/0001193125-26-353891.md) |
| Interest expense | $m | [0.6](/filings/0000851310-23-000097.md) | [0.6 d](/filings/0000851310-24-000024.md) | [0.7](/filings/0000851310-24-000049.md) | [1.4](/filings/0000851310-25-000076.md) | [2.7](/filings/0001193125-25-264696.md) | [1.6 d](/filings/0001193125-26-067506.md) | [1.3](/filings/0001193125-26-221899.md) | [1.1](/filings/0001193125-26-353891.md) | [1.2](/filings/0001193125-25-264696.md) | [(0.1) d](/filings/0001193125-26-067506.md) | [1.1](/filings/0001193125-26-221899.md) | [1.1](/filings/0001193125-26-353891.md) |
| Income tax | $m | [(2.4)](/filings/0000851310-24-000094.md) | [(70.7) d](/filings/0001193125-26-067506.md) | [(2.4)](/filings/0000851310-25-000041.md) | [(3.9)](/filings/0000851310-25-000076.md) | [7.1](/filings/0001193125-25-264696.md) | [20.1 d](/filings/0001193125-26-067506.md) | [2.7](/filings/0001193125-26-221899.md) | [(2.2)](/filings/0001193125-26-353891.md) | [6.1](/filings/0001193125-25-264696.md) | [(1.1) d](/filings/0001193125-26-067506.md) | [9.7](/filings/0001193125-26-221899.md) | [4.9](/filings/0001193125-26-353891.md) |
| Net income | $m | [(6.5)](/filings/0000851310-24-000094.md) | [83.8 d](/filings/0001193125-26-067506.md) | [(8.1)](/filings/0000851310-25-000041.md) | [(12.5)](/filings/0000851310-25-000076.md) | [21.7](/filings/0001193125-25-264696.md) | [38.1 d](/filings/0001193125-26-067506.md) | [5.9](/filings/0001193125-26-221899.md) | [2.9](/filings/0001193125-26-353891.md) | [2.7](/filings/0001193125-25-264696.md) | [(54.8) d](/filings/0001193125-26-067506.md) | [7.3](/filings/0001193125-26-221899.md) | [(2.3)](/filings/0001193125-26-353891.md) |
| Diluted EPS | $ per share | [(0.06)](/filings/0000851310-24-000094.md) | not reported | [(0.07)](/filings/0000851310-25-000041.md) | [(0.11)](/filings/0000851310-25-000076.md) | [0.19](/filings/0001193125-25-264696.md) | not reported | [0.05](/filings/0001193125-26-221899.md) | [0.03](/filings/0001193125-26-353891.md) | [0.02](/filings/0001193125-25-264696.md) | not reported | [0.07](/filings/0001193125-26-221899.md) | [(0.02)](/filings/0001193125-26-353891.md) |
| Basic EPS | $ per share | [(0.06)](/filings/0000851310-24-000094.md) | not reported | [(0.07)](/filings/0000851310-25-000041.md) | [(0.11)](/filings/0000851310-25-000076.md) | [0.19](/filings/0001193125-25-264696.md) | not reported | [0.05](/filings/0001193125-26-221899.md) | [0.03](/filings/0001193125-26-353891.md) | [0.02](/filings/0001193125-25-264696.md) | not reported | [0.07](/filings/0001193125-26-221899.md) | [(0.02)](/filings/0001193125-26-353891.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-29) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [75.6](/filings/0000851310-24-000094.md) | [84.3](/filings/0001193125-26-067506.md) | [84.3](/filings/0000851310-25-000041.md) | [45.9](/filings/0000851310-25-000076.md) | [58.2](/filings/0001193125-25-264696.md) | [101](/filings/0001193125-26-067506.md) | [149](/filings/0001193125-26-221899.md) | [124](/filings/0001193125-26-353891.md) | [127](/filings/0001193125-25-264696.md) | [124](/filings/0001193125-26-353891.md) | [109](/filings/0001193125-26-221899.md) | [232](/filings/0001193125-26-353891.md) |
| Current assets | $m | [329](/filings/0000851310-23-000097.md) | [331](/filings/0000851310-25-000021.md) | [301](/filings/0000851310-24-000049.md) | [285](/filings/0000851310-24-000074.md) | [336](/filings/0000851310-24-000094.md) | [565](/filings/0001193125-26-067506.md) | [341](/filings/0000851310-25-000041.md) | [343](/filings/0000851310-25-000076.md) | [327](/filings/0001193125-25-264696.md) | [494](/filings/0001193125-26-353891.md) | [485](/filings/0001193125-26-221899.md) | [417](/filings/0001193125-26-353891.md) |
| Total assets | $m | [674](/filings/0000851310-23-000097.md) | [768](/filings/0000851310-25-000021.md) | [741](/filings/0000851310-24-000049.md) | [714](/filings/0000851310-24-000074.md) | [760](/filings/0000851310-24-000094.md) | [797](/filings/0001193125-26-067506.md) | [774](/filings/0000851310-25-000041.md) | [783](/filings/0000851310-25-000076.md) | [759](/filings/0001193125-25-264696.md) | [718](/filings/0001193125-26-353891.md) | [705](/filings/0001193125-26-221899.md) | [633](/filings/0001193125-26-353891.md) |
| Current liabilities | $m | [275](/filings/0000851310-23-000097.md) | [272](/filings/0000851310-25-000021.md) | [275](/filings/0000851310-24-000049.md) | [152](/filings/0000851310-24-000074.md) | [162](/filings/0000851310-24-000094.md) | [192](/filings/0001193125-26-067506.md) | [165](/filings/0000851310-25-000041.md) | [172](/filings/0000851310-25-000076.md) | [157](/filings/0001193125-25-264696.md) | [198](/filings/0001193125-26-353891.md) | [214](/filings/0001193125-26-221899.md) | [137](/filings/0001193125-26-353891.md) |
| Total liabilities | $m | [333](/filings/0000851310-23-000097.md) | [331](/filings/0000851310-25-000021.md) | [332](/filings/0000851310-24-000049.md) | [321](/filings/0000851310-24-000074.md) | [331](/filings/0000851310-24-000094.md) | [331](/filings/0001193125-26-067506.md) | [328](/filings/0000851310-25-000041.md) | [337](/filings/0000851310-25-000076.md) | [316](/filings/0001193125-25-264696.md) | [335](/filings/0001193125-26-353891.md) | [350](/filings/0001193125-26-221899.md) | [272](/filings/0001193125-26-353891.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0000851310-25-000021.md) | not reported | [114](/filings/0000851310-24-000074.md) | [113](/filings/0000851310-24-000094.md) | [112](/filings/0001193125-26-067506.md) | [111](/filings/0000851310-25-000041.md) | [111](/filings/0000851310-25-000076.md) | [110](/filings/0001193125-25-264696.md) | [109](/filings/0001193125-26-353891.md) | [108](/filings/0001193125-26-221899.md) | [108](/filings/0001193125-26-353891.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [2.2](/filings/0001193125-26-067506.md) | not reported | [2.7](/filings/0000851310-25-000076.md) | [2.9](/filings/0001193125-25-264696.md) | [2.9](/filings/0001193125-26-353891.md) | [2.9](/filings/0001193125-26-221899.md) | [2.9](/filings/0001193125-26-353891.md) |
| Shareholders' equity | $m | [341](/filings/0000851310-24-000094.md) | [437](/filings/0001193125-26-067506.md) | [409](/filings/0000851310-25-000076.md) | [393](/filings/0001193125-25-264696.md) | [429](/filings/0001193125-25-264696.md) | [465](/filings/0001193125-26-353891.md) | [446](/filings/0001193125-26-353891.md) | [446](/filings/0001193125-26-353891.md) | [443](/filings/0001193125-25-264696.md) | [383](/filings/0001193125-26-353891.md) | [355](/filings/0001193125-26-353891.md) | [360](/filings/0001193125-26-353891.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-29) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [11.0 d](/filings/0000851310-24-000094.md) | [6.3 d](/filings/0001193125-26-067506.md) | [26.8](/filings/0000851310-25-000041.md) | [(22.2) d](/filings/0000851310-25-000076.md) | [8.7 d](/filings/0001193125-25-264696.md) | [48.5 d](/filings/0001193125-26-067506.md) | [83.6](/filings/0001193125-26-221899.md) | [(11.7) d](/filings/0001193125-26-353891.md) | [23.8 d](/filings/0001193125-25-264696.md) | [12.3 d](/filings/0001193125-26-067506.md) | [31.7](/filings/0001193125-26-221899.md) | [(58.0) d](/filings/0001193125-26-353891.md) |
| Capital expenditure | $m | [1.9 d](/filings/0000851310-24-000094.md) | [2.7 d](/filings/0001193125-26-067506.md) | [1.9](/filings/0000851310-25-000041.md) | [1.9 d](/filings/0000851310-25-000076.md) | [3.0 d](/filings/0001193125-25-264696.md) | [2.3 d](/filings/0001193125-26-067506.md) | [1.9](/filings/0001193125-26-221899.md) | [3.8 d](/filings/0001193125-26-353891.md) | [2.7 d](/filings/0001193125-25-264696.md) | [2.7 d](/filings/0001193125-26-067506.md) | [1.4](/filings/0001193125-26-221899.md) | [1.6 d](/filings/0001193125-26-353891.md) |
| Share repurchases | $m | [0.0 d](/filings/0000851310-24-000094.md) | [0.0 d](/filings/0001193125-26-067506.md) | [21.7](/filings/0000851310-25-000041.md) | [8.4 d](/filings/0000851310-25-000076.md) | [0.0 d](/filings/0001193125-25-264696.md) | [0.0 d](/filings/0001193125-26-067506.md) | [36.1](/filings/0001193125-26-221899.md) | [14.0 d](/filings/0001193125-26-353891.md) | [15.7 d](/filings/0001193125-25-264696.md) | [13.3 d](/filings/0001193125-26-067506.md) | [43.0](/filings/0001193125-26-221899.md) | [(0.0) d](/filings/0001193125-26-353891.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [113](/filings/0000851310-23-000097.md) | [118](/filings/0000851310-24-000049.md) | [119](/filings/0000851310-24-000074.md) | [112](/filings/0000851310-24-000094.md) | [112](/filings/0000851310-25-000041.md) | [115](/filings/0000851310-25-000076.md) | [117](/filings/0001193125-25-264696.md) | [117](/filings/0001193125-26-221899.md) | [113](/filings/0001193125-26-353891.md) | [113](/filings/0001193125-25-264696.md) | [111](/filings/0001193125-26-221899.md) | [110](/filings/0001193125-26-353891.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 109,066,445 at 2026-08-03, from the cover of the [10-Q filed 2026-08-17](/filings/0001193125-26-353891.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.